Folgen
Keine Story von Pfizer AG mehr verpassen.

Pfizer AG

Filtern
  • 08.06.2010 – 07:01

    Football Stars Unite to Tackle Back Pain

    Rome, June 8, 2010 (ots/PRNewswire) - UK Premiership footballer Rory Delap, renowned for his devastating throw-in, has joined forces with a number of football heroes across Europe to support 'Back in Play', a European wide campaign to reach young men and women and raise awareness of ankylosing spondylitis (AS), a poorly understood condition which can affect the lower back. To view the Multimedia News Release, ...

  • 12.10.2008 – 01:07

    Europeans Face a Painful Truth on First Ever Neuropathic Pain Day - October 13

    London (ots/PRNewswire) - - Not for UK Journalists - New Survey Reveals Widespread Ignorance of Debilitating Pain Condition Affecting Millions of Europeans Alarmingly, nearly sixty per cent of Europeans have never heard of neuropathic pain (NeP), (1) a debilitating nerve condition that affects approximately 22 million people, (2),(3) according to ...

  • 23.02.2007 – 14:57

    Danish Court Issues Preliminary Injunction That Prohibits Sale of Generic Lipitor Product

    New York (ots/PRNewswire) - Pfizer Inc said today that a Danish court has granted a preliminary injunction against Nomeco A/S -- the largest pharmaceutical wholesaler in Denmark -- that prohibits the sale of a generic version of Lipitor by generics manufacturer Ranbaxy. The injunction, issued by the Bailiff's Court of the Copenhagen City Court in Denmark and ...

  • 23.02.2007 – 10:05

    Celebrex Label Extended for New Use in Europe

    New York (ots/PRNewswire) - - Celebrex to be Available in Europe for the Treatment of Ankylosing Spondylitis, a Debilitating Form of Arthritis Pfizer Inc announced today that 17 European countries agreed to extend the Celebrex (celecoxib capsules) label to include symptomatic relief in the treatment of ankylosing spondylitis (in adults), a form of arthritis that affects the spine. Once each country updates ...

  • 13.02.2007 – 13:09

    Pfizer's Maraviroc to Receive Accelerated Regulatory Reviews in the U.S. and Europe

    New York (ots/PRNewswire) - - If Approved, Maraviroc will be the First in a New Class of Medications Available for HIV Treatment Pfizer announced today that marketing authorization applications for maraviroc will receive accelerated review in both the United States and Europe. Accelerated reviews are granted to potential medicines that, if approved, would ...